ASX-Dividend-Report-Banner

Singleron launches the AccuraSCOPE® Single Cell Transcriptome

January 30, 2024 09:05 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Singleron launches the AccuraSCOPE® Single Cell Transcriptome
Image source: Kalkine Media

COLOGNE, Germany, Jan. 30, 2024 /PRNewswire/ -- Singleron Biotechnologies, a leader in single cell multi-omic solutions for precision medicine, announced two new commercial product launches : AccuraSCOPE® Single Cell Transcriptome and Genome Library Kit and the AccuraSCOPE® Single Cell Full-Length Transcriptome Library Kit.

AccuraSCOPE  Single Cell Transcriptome and Genome Library Kit opens new possibilities for single cell multi-omic analysis by profiling the entire genome and transcriptome simultaneously. In addition to single cell RNA sequencing, this method enables deep single cell genome sequencing, amplifying ultra-low quantities of DNA from individual cells. This facilitates the comprehensive detection of single nucleotide variants and chromosomal aberrations at single cell level. Using proprietary bead-based technology, it captures both genomic DNA and mRNA from each cell and converts them to high-quality sequencing libraries. The integrated analysis of a cell's transcriptome and genome provides a comprehensive understanding of cellular heterogeneity in normal development and disease. The kit's multiplex design and streamlined workflow allow for single-cell mRNA and DNA library preparation from up to 384 single cells in parallel in a single day, significantly reducing time and costs.

Another new product in the AccuraSCOPE portfolio, AccuraSCOPE Single Cell Full-Length Transcriptome Library Kit, adds full-length, comprehensive, and rapid RNA sequencing library preparation to the toolkit. It enables the detection of alternative splicing at the single cell level, substantially reducing hands-on time compared to existing full-length single cell RNAseq methods.

The latest innovations were developed to particularly aid clinical researchers in oncology, gene, and cell therapy, as well as immunology and reproductive biology. Accurate detection of genomic and transcriptomic changes can unveil the relationship between genomic dynamics and gene expression profiles as well as uncover the functional impact of point mutations and copy number variations.

To meet customers' data analysis needs when using the new AccuraSCOPE products, Singleron has developed two bioinformatic analysis pipelines. The RNA sequencing data analysis pipeline covers the analysis workflow from FASTQ files to count matrix, while the DNA data analysis pipeline starts with FASTQ files and includes variance calling and variant annotation.

Both kits are compatible with well-based automation workstation, flow cytometry cell sorting, or micropipette aspiration. For more detailed information on the product please visit: https://singleron.bio/product/detail-30.html

About Singleron: 

Singleron biotechnologies advances precision medicine and human health through pioneering single cell multi-omics solutions. Its current product portfolio includes high throughput instruments for automated single cell processing and tissue dissociation, reagents, bioinformatics software, and a comprehensive single cell knowledgebase.

Founded in 2018, Singleron operates globally with offices, laboratories, and manufacturing facilities in Germany, Singapore, China, and the US. Its products are used in over 3000 laboratories in hospitals, research institutes, and pharmaceutical companies in more than 20 countries.

Learn more at https://singleron.bio

Media Contact: Rahel Oeser, [email protected]


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.